

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity NEUROTECH INTERNATIONAL LIMITED
ACN 610 205 402

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Griffiths
Date of last notice	12 May 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Shimano Ventures Limited – indirect interest as a partner of Shimano Ventures Limited
Date of change	25 February 2019
No. of securities held prior to change	4,657,588 Ordinary Fully Paid shares 2,060,334 Options exercise price \$0.20 each expiring 30 November 2020.
Class	Fully Paid Ordinary Shares Options exercise price \$0.06 each expiring 30 November 2020.
Number acquired	2,634,790 Ordinary Fully Paid shares 2,634,790 Options.
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$79,043.70

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	7,292,378 Ordinary Fully Paid shares 2,060,334 Options exercise price \$0.20 each expiring 30 November 2020. 2,634,790 Options. Exercise price \$0.06 each expiring 31 March 2021
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares and options pursuant to Rights offer. Shares issued at \$0.03, with one free attaching option issued for each share applied for.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Consultancy Services Agreement
Nature of interest	Engagement as CEO and Managing Director of Neurotech International Limited
Name of registered holder (if issued securities)	N/A
Date of change	29 January 2019
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Interest acquired</p>	<p>Subject to shareholder approval:</p> <ul style="list-style-type: none"> • 6,500,000 Options, exercisable at A\$0.0589 per Share (Tranche 1 Options); and • The number of Options equivalent to 4% of the total Shares on issue at 30 June 2019, with exercise price determined by reference to the performance of the Company's share price to 30 June 2019 or the issue price of Shares in a capital raising, as relevant (Tranche 2 Options). <p>A full summary of the terms and conditions of the Mr Griffiths' appointment and the terms of the proposed options are included at sections of 9.7 and 9.8 of the Company's prospectus for a renounceable pro-rata rights issue to be lodged with ASIC and released to ASX on 29 January 2019</p>
<p>Interest disposed</p>	<p>N/A</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation</p>	<p>N/A</p>
<p>Interest after change</p>	<p>Subject to shareholder approval:</p> <ul style="list-style-type: none"> • 6,500,000 Options, exercisable at A\$0.0589 per Share (Tranche 1 Options); and • The number of Options equivalent to 4% of the total Shares on issue at 30 June 2019, with exercise price determined by reference to the performance of the Company's share price to 30 June 2019 or the issue price of Shares in a capital raising, as relevant (Tranche 2 Options).

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.